Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 3, 2015, Pages 523-529

  Woehlecke, Caroline ^a   Wittig, Susan ^a   Arndt, Clemens ^a   Gruhn, Bernd ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Acute myeloid leukemia (AML); Hematopoietic stem cell transplantation (HSCT); Minimal residual disease (MRD); Myelodysplastic syndrome (MDS); Wilms tumor gene 1 (WT1) expression

Indexed keywords

BUSULFAN; MESSENGER RNA; WT1 PROTEIN; TUMOR MARKER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHRONIC MYELOID LEUKEMIA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL DEPLETION; WHOLE BODY RADIATION; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; HEMATOLOGIC DISEASES; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 84925504940     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1832-y     Document Type: Article

References (21)

1. Bader P et al (2004) WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol 73:25–28. doi:10.1111/j.1600-0609.2004.00260.x
2. Boublikova L et al (2006) Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20:254–263. doi:10.1038/sj.leu.2404047
3. Call KM et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60:509–520
4. Cazzaniga G, dA E, Corral L, Biondi A (2003) Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. Best pract res Clin haematol 15:623–638
5. Cilloni D, Saglio G (2004) WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112:79–84. doi:10.1159/000077562
6. Cilloni D et al (2003) Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J clin oncol: Off J American Soc Clin Oncol 21:1988–1995. doi:10.1200/JCO.2003.10.503
7. Gaiger A et al (1999) Wilms’ tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur J Haematol 63:86–93
8. Hosen N et al (2002) Very low frequencies of human normal CD34 + haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 116:409–420
9. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84(9):3071–3079
10. Jacobsohn DA et al (2009) High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 146:669–674. doi:10.1111/j.1365-2141.2009.07770.x
11. Kwon M et al (2012) Evaluation of minimal residual disease by real-time quantitative PCR of Wilms’ tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplantation 18:1235–1242. doi:10.1016/j.bbmt.2012.01.012
12. Lange T et al (2011) Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25:498–505. doi:10.1038/leu.2010.283
13. Ogawa H et al (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101:1698–1704. doi:10.1182/blood-2002-06-1831
14. Rossi G et al (2012) Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res 36:401–406. doi:10.1016/j.leukres.2011.11.020
15. Sugiyama H (2001) Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73:177–187
16. Sugiyama H (2010) WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40:377–387. doi:10.1093/jjco/hyp194
17. Tamaki H et al (1999) The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13:393–399
18. Trka J et al (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16:1381–1389. doi:10.1038/sj.leu.2402512
19. Valkova V et al (2013) Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. Clin Transplant 27:E21–29. doi:10.1111/ctr.12046
20. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S (2005) Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19:1416–1423. doi:10.1038/sj.leu.2403809
21. Zhao XS et al (2013) Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol 92:1111–1119. doi:10.1007/s00277-013-1733-1